Trailing-twelve-month (TTM) revenue is $77.68 Million with a year-over-year growth of +35.89%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $8,601,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $38,915,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-11 |
| Q1 FY2026Period ended 2026-03-31 | $15,248,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $14,915,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $77,679,000 |
Current P/S: $150,048,166 market capitalization ÷ $77,679,000 TTM revenue = 1.93x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T13:34:55.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $14.91M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:36:00.014Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Enzyme Product | N/A | $2M | $75M | $8M | N/A | N/A |
| Product | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Americas | $24M | $23M | $17M | $14M | $21M | $44M |
| APAC | $25M | N/A | N/A | N/A |
$77.68M
$77.68 Million
+35.89%
vs. $57.16M a year ago (TTM)
+0.38%
5 Year compound annual growth rate
1 Year
+35.89%
3 Year
+1.80%
5 Year
+0.38%
10 Year
+3.90%
15 Year
(2.53%)
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $70.39M | +$11.04M | +18.61% |
| 2024 | $59.34M | ($10.80M) | (15.39%) |
| 2023 | $70.14M | ($68.45M) | (49.39%) |
| 2022 | $138.59M | +$33.84M | +32.30% |
| 2021 | $104.75M | +$35.70M | +51.69% |
| 2020 |
TTM Growth
+35.89%
3-Year CAGR
+1.80%
5-Year CAGR
+0.38%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T13:36:00.014Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $37M |
| $26M |
| Product Sales | $2M | $3M | $29M | N/A | N/A | N/A |
|---|
| Research and Development Revenue | $2M | $3M | $2M | $27M | $23M | N/A |
|---|
| Research And Development Revenue | N/A | N/A | N/A | N/A | N/A | $44M |
|---|
| Service | $39M | $34M | N/A | N/A | N/A | N/A |
|---|
| Sitagliptin Enzyme | N/A | $3M | $2M | N/A | $3M | N/A |
|---|
| N/A |
| N/A |
| Asia Pacific | N/A | $61M | $65M | $34M | $28M | $18M |
|---|
| CHINA | N/A | N/A | N/A | $20M | $10M | $9M |
|---|
| EMEA | $19M | $20M | $57M | $23M | $10M | $9M |
|---|
| INDIA | N/A | N/A | N/A | N/A | $7M | $6M |
|---|
| IRELAND | N/A | N/A | N/A | $500,000 | $2M | $700,000 |
|---|
| SINGAPORE | N/A | N/A | N/A | N/A | $6M | $400,000 |
|---|
| SWITZERLAND | N/A | N/A | N/A | $11M | $3M | $4M |
|---|
| UNITED STATES | N/A | N/A | N/A | $14M | $21M | $44M |
|---|
| $69.06M |
| +$598,000 |
| +0.87% |
| 2019 | $68.46M | +$7.86M | +12.98% |
| 2018 | $60.59M | +$10.57M | +21.13% |
| 2017 | $50.02M | +$1.19M | +2.43% |
| 2016 | $48.84M | +$7.03M | +16.82% |
